This was consistent with the reports that inhibition of PI3K/Akt or mTOR signaling pathways could enhance the chemotherapeutic efficacy of gemcitabine on pancreatic cancer patients34,35. The gene discussed is AKT1; the disease is pancreatic neoplasm.